SCHEMBL1587773

SCHEMBL1587773

CC1(C)OC(=O)C(=Cc2ccccc2)C(=O)O1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.66
CRHBP P24387 3/20 0.66
CRHR2 Q13324 3/20 0.66
SIRT1 Q96EB6 2/20 0.58
KMT2A Q03164 5/20 0.56
HPGD P15428 3/20 0.50
MEN1 O00255 3/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 1/20 0.44
CYP1A2 P05177 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP3A4 P08684 2/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
EP300 Q09472 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21601096 0.85 SIRT1 (0.79) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL17199432 0.84 ALDH1A1 (0.67) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL12345520 0.82 ALDH1A1 (0.65) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL2074007 0.82 ALDH1A1 (0.65) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL658436 0.82 ALDH1A1 (0.65) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL2074727 0.82 ALDH1A1 (0.60) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL435198 0.82 SIRT1 (0.71) ALDH1A1CRHBPCRHR2SIRT1KMT2A
SCHEMBL3076077 0.80 KMT2A (0.65) ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL9196949 0.80 ALDH1A1 (1.00) ALDH1A1CRHBPCRHR2KMT2AHPGD
SCHEMBL3076148 0.80 KMT2A (0.56) ALDH1A1CRHBPCRHR2SIRT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3737470-B1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2022-12-14 EP disclosed
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof NATIONAL GUARD HEALTH AFFAIRS (SA) 2021-11-02 US disclosed
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF NATIONAL GUARD HEALTH AFFAIRS (SA) 2020-09-17 US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-8383642-B2 Spiropiperidine compounds ELI LILLY AND COMPANY (US) 2013-02-26 US disclosed
US-20110092531-A1 Novel Spiropiperidine Compounds ELI LILLY AND COMPANY (US) 2011-04-21 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 WO disclosed
US-7790882-B2 Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst Carreira, Erick M. (CH) 2010-09-07 US disclosed
US-20050277772-A1 Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst Carreira, Erick (CH) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof PDK1, PDHA1, PDHA2 ALDH1A1 7/4885CRHBP 3904/4885CRHR2 3663/4885
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 ALDH1A1 1903/4885CRHBP 2876/4885CRHR2 930/4885
US-20110092531-A1 Novel Spiropiperidine Compounds REN, SLC5A1, SLC5A2 ALDH1A1 564/4885CRHBP 1360/4885CRHR2 1090/4885
US-20050277772-A1 Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst C1R, ARL1, C5 ALDH1A1 2507/4885CRHBP 4732/4885CRHR2 3803/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 ALDH1A1 2399/4885CRHBP 2850/4885CRHR2 646/4885
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF PDK1, PDHA1, PDHA2 ALDH1A1 7/4885CRHBP 3904/4885CRHR2 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.